The Medicines Patent Pool (MPP) welcomes a research collaboration agreement between U.S. government researchers and Afrigen Biologics for the development of next-generation mRNA vaccines and therapeutics.

The agreement between Afrigen and the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health, includes the exchange of scientific expertise that may be used to make mRNA vaccines.

Afrigen is part of the mRNA technology transfer hub programme, a global initiative designed to establish sustainable, locally owned mRNA manufacturing capabilities in and for low- and middle-income countries (LMICs).

“We at MPP are delighted to see these research agreements aimed at building vaccine manufacturing capacity in LMICs,” said Charles Gore, Executive Director of MPP. “Sharing know-how and expertise is about expanding global access to essential medicines.”

Access announcement of collaboration agreement

Read more on the Hub